He C, Mi X, Xu G, Xu X, et al. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. PLoS One 2024;19:e0302961.
PMID: 38748691